Pfizer Corporation

Seungil Han

Eddine Saiah

Christoph Wolfgang Zapf

Christoph Martin Dehnhardt

Joseph Walter Strohbach

David Hepworth

Arthur Lee

Nikolaos Papaioannou

Frank Eldridge Lovering

Katherine Lin Lee

Stephen Wayne Wright

John David Trzupek

Lori Krim Gavrin

John Paul Mathias

Akshay Patny

Kevin Joseph Curran

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

Betsy Susan Pierce

Balekudru Devadas

Margaret Lanahan Grapperhaus

Susan Landis Hockerman

Shaun Raj Selness

Mark E Schnute

Li Huang Xing

Robert Owen Hughes

Daniel Patrick Walker

Dafydd Rhys Owen

Zhao-Kui Wan

John Robert Springer

Christophe Philippe Allais

Michelle Ann Schmidt

Danny James Garland

Matthew Frank Brown

Philip R Dormitzer

Thomas Richard Jones

Ye Che

Xiayang Qiu

Mark J Mitton-Fry

Manjinder Singh Lall

Matthew Curtis Griffor

Xiaoyuan Sherry Chi

Mark Stephen Plummer

Jennifer Anne Nicki

Xiaojie Yao

Yuhang Liu

Xinzhen Yang

Hud Lawrence Risley

Joel Adam Goldberg

Veerabahu Shanmugasundaram

Kyle Paul Heim

Mark Edward Schnute

David Randolph Anderson

Jeremy T Starr

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

Human cytomegalovirus gB polypeptide

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I) 

Bruton's tyrosine kinase inhibitors

Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. 

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. 

Growing community of inventors

Mystic, CT, United States of America

Seungil Han